What is Beijing Airdoc Technology Co 1-Year ROIIC %?
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Beijing Airdoc Technology Co's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was 14.19%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
HKSE:02251's 1-Year ROIIC % is ranked better than 63.19% of 633
companies
in the Healthcare Providers & Services industry
Industry Median: 3.01
vs HKSE:02251: 14.19
Beijing Airdoc Technology Co 1-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beijing Airdoc Technology Co's 1-Year ROIIC %
For the Health Information Services subindustry, Beijing Airdoc Technology Co's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Airdoc Technology Co's 1-Year ROIIC % Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Beijing Airdoc Technology Co's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Beijing Airdoc Technology Co's 1-Year ROIIC % falls into.
Beijing Airdoc Technology Co 1-Year ROIIC % Calculation
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Beijing Airdoc Technology Co (HKSE:02251) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Beijing Airdoc Technology Co 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Beijing Airdoc Technology Co's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Beijing Airdoc Technology Co (HKSE:02251) Business Description
Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue principally from the provision of AI-based software solutions, sales of hardware devices and other services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02251 has been successfully added to your 